HER2

Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

by
Professor Liu Yunjian: Interpreting the DS8201-A-U105 Study and Discussing the Future of ADC Combined Immunotherapy

Introduction The DS8201-A-U105 study reveals the latest advancements in ADC combined immunotherapy. What insights can we draw from it? The annual European Society for Medical Oncology Breast Cancer (ESMO BC) conference was officially held from May 3-5, 2022, reporting a series of significant advancements in the field of breast cancer. ADCs have become star drugs … Read more

ADC Resistance Overcome: ORR Exceeds 41%! The Potential of HER2 TKI Treatment in HER2+ NSCLC

by
ADC Resistance Overcome: ORR Exceeds 41%! The Potential of HER2 TKI Treatment in HER2+ NSCLC

Introduction Zongertinib (BI1810631) is a selective HER2 (ERBB2) tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which covalently binds to the receptor tyrosine kinase domain (TKD) of HER2 exon 20 mutations. This selectivity allows it to block only the abnormal downstream signaling of HER2 without affecting the wild-type epidermal growth factor receptor (wtEGFR, i.e., normal … Read more

ADC on the Edge: The Struggles of Chinese Pharmaceutical Companies Amid Technical Shortcomings and Capital Withdrawal

by
ADC on the Edge: The Struggles of Chinese Pharmaceutical Companies Amid Technical Shortcomings and Capital Withdrawal

This March, the American biotechnology company Elevation Oncology announced the termination of the development pipeline for EO-3021 (Claudin 18.2 ADC) licensed from Shiyao Group, redirecting resources to EO-1022 (HER-3 ADC).In July 2022, Shiyao Group licensed EO-3021 to Elevation, which paid a $27 million upfront fee along with potential milestone payments of up to $1.148 billion … Read more

Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

by
Lancet Oncology Publishes! Efficacy and Safety of DS-8201 in Treating HER2-Positive Lung Cancer

Source: Professor Zhang Bo The activation mechanisms of the HER-2 gene include amplification, mutation, insertion, and protein overexpression. Although HER-2 is considered a driver gene in lung cancer, no targeted therapeutic drugs have been approved. Recently, Lancet Oncology published efficacy and safety data for the ADC drug DS-8201 targeting HER2 in patients with advanced NSCLC … Read more

New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

by
New Hope for Long-Term Survival in Late-Stage Patients: Overview of Five Major Targeted Drugs and Clinical Trials for Non-Small Cell Lung Cancer

EGFR In the Chinese patient population, EGFR is the most common driver gene mutation type in non-small cell lung cancer and is also one of the gene types with relatively good efficacy. However, even for this type of non-small cell lung cancer, there are still some “blind spots” in targeted therapy, such as certain difficult-to-treat … Read more

Understanding Targeted Therapies for HER2-Positive Advanced Breast Cancer: Focus on Five Categories

by

The human epidermal growth factor receptor 2 (HER2) is a known important molecular target in breast cancer. As one of the proto-oncogenes, HER2 is often associated with aggressiveness, recurrence, metastasis, and poor prognosis. The clinical application of the anti-HER2 drug trastuzumab has significantly improved the diagnosis and treatment patterns and prognosis of HER2-positive breast cancer, … Read more

Key Details Not to Ignore in ADC Drug Treatment

by
Key Details Not to Ignore in ADC Drug Treatment

Click below to follow and learn more about anti-cancer knowledge 👇 For patients with HER2 mutations in non-small cell lung cancer, past treatments have primarily involved chemotherapy, immunotherapy combined with chemotherapy, and anti-angiogenic therapy combined with chemotherapy. With the rise of antibody-drug conjugates (ADC), the treatment prospects for HER2 mutation patients are becoming increasingly clear. … Read more

Technical Insights into 15 ADC Drugs and Future Innovations

by
Technical Insights into 15 ADC Drugs and Future Innovations

GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more

The Amazing ‘Magic Bullet’ – Antibody-Drug Conjugates (ADCs)

by
The Amazing 'Magic Bullet' - Antibody-Drug Conjugates (ADCs)

The Concept and Development History of ADC The treatment of tumors has always undergone a continuous transformation from theory to application, breaking and transforming again. As early as a century ago, scholars proposed the concept of antibody-drug conjugates (ADCs), vividly calling them “magic bullets,” aimed at targeting specific antigens that may exist on the surface … Read more

15 ADC Drugs: Dosage and Usage Summary

by
15 ADC Drugs: Dosage and Usage Summary

Currently, there are 15 ADC drugs approved globally, among which 6 ADC drugs have been approved in China, namely Trastuzumab emtansine, Brentuximab vedotin, Trastuzumab deruxtecan, Vidofludimus, Gemtuzumab ozogamicin, and Sacituzumab govitecan. This article provides a brief summary based on the currently approved ADC drugs worldwide, the types of tumors they are suitable for, and how … Read more